Evidence map›Paper›PMID 40117097›Full record

ArticleInternational journal of hematology2025

DLI-induced remission in recurrent EBV-associated T/NK-cell lymphoproliferative disease following HSCT: a case report.

Toru Nagata, Hirohito Kubota, Itaru Kato, Kazushi Izawa, Ryo Akazawa, Tomoyasu Jo, Yasuyuki Arai, Shohei Azumi, Tatsuya Kamitori, Satoshi Saida and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Toru NagataDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Hirohito KubotaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Itaru KatoDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan. itarkt@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-2932-4960
Kazushi IzawaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Ryo AkazawaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Tomoyasu JoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasuyuki AraiDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shohei AzumiDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Tatsuya KamitoriDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Satoshi SaidaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Katsutsugu UmedaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Ken-Ichi ImadomeDepartment of Advanced Medicine for Infections, National Center for Child Health and Development (NCCHD), Tokyo, Japan.
Takahiro YasumiDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Hidefumi HiramatsuDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.
Junko TakitaDepartment of Pediatrics, Kyoto University Hospital, 54 Syogoin Kawaramachi Sakyo-Ku, Kyoto, 606-8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpstein-Barr virus (EBV)-associated T/natural killer (NK)-cell lymphoproliferative diseases (T/NK-LPDs) are characterized by clonal proliferation of EBV-infected T or NK cells, and the only curative treatment for progressive T/NK-LPDs is allogeneic hematopoietic stem cell transplantation (HSCT). There are limited reports concerning optimal management strategies for disease relapse after HSCT in patients with EBV-associated T/NK-LPDs. CASE PRESENTATION: A 2-year-old girl was diagnosed with severe mosquito bite allergy, a cutaneous form of EBV-associated T/NK-LPD. Following HSCT from her human leukocyte antigen-matched sister, complete donor-type chimerism was achieved and whole blood EBV-DNA load became undetectable. However, the whole blood EBV-DNA load became elevated again and donor type chimerism decreased. Donor lymphocyte infusion (DLI) was performed to control the disease relapse. A complete virological response and complete donor-type chimerism were attained after four doses of DLI. No adverse effects were observed during the treatment course.

conclusionsThis case highlights the potential of DLI as an alternative therapeutic approach to re-transplantation for recurrent EBV-associated T/NK-LPDs.

Indexed as

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanKiller Cells, NaturalLymphocyte TransfusionLymphoproliferative DisordersT-LymphocytesChild, PreschoolFemaleHumansRecurrenceRemission InductionCAEBVDLIHSCTLPDSMBAT/NK

Identifiers

PMID40117097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.